Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
2
Neutral
7
Bullish
5
Bearish
10
Neutral
7
Bullish
29
Bearish
8
Neutral
0
Bullish
24
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc.
The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing.
BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation.
Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification.
The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.
Pharmaceuticals & Biotechnology
Pharmaceuticals
139 Cr
Low Risk
22.1
36.7
-1.7
1.7
112.97
59.69
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY23
Investor Presentation
Q3 FY23
Investor Presentation
Q1 FY23
Investor Presentation
Q1 FY23
Bal Pharma Ltd (BALPHARMA) is currently trading at 87.08 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc. The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing. BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation. Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification. The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.
Over the past 52 weeks, Bal Pharma Ltd has traded between a low of ₹59.69 and a high of ₹112.97. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bal Pharma Ltd has a market capitalization of approximately 138.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 138.64 Cr, Bal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bal Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bal Pharma Ltd is 22.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
147.75 | 151 Cr | — | 0.86 | 0.00 | -7.27 | -4.85 | -5.82 | ||
31.70 | 151 Cr | 20.32 | 8.52 | 0.00 | 41.95 | 22.81 | 7.20 | ||
67.00 | 141 Cr | 9.40 | 0.76 | 0.00 | 8.06 | 8.98 | 6.13 | ||
87.08 | 139 Cr | 22.05 | 1.69 | 1.38 | 7.64 | 9.18 | 1.68 | ||
113.05 | 130 Cr | 34.86 | 1.78 | 1.32 | 4.66 | 7.75 | 3.31 | ||
126.50 | 130 Cr | 18.69 | 0.92 | 2.77 | 4.94 | 6.74 | 4.67 | ||
100.00 | 126 Cr | 20.75 | 1.94 | 0.00 | 9.36 | 10.75 | 3.31 | ||
| Median: 7 Co. | — | 100.00 | 139 Cr | 20.54 | 1.69 | 0.00 | 7.64 | 8.98 | 3.31 |
Preferential Allotment/QIP
Bal Pharma issued a corrigendum to its 09-Jul-2026 postal ballot: revises preferential issue of 10,00,000 warrants to promoter — price increased from ₹81 to ₹84 (aggregate ₹8.4 Cr); payment terms and objects (Greenfield API plant at Yadgiri) updated. Remote e‑voting: 10‑Jul‑2026 to 08‑Aug‑2026.
Preferential Allotment/QIP
Bal Pharma Ltd issued a corrigendum to the July 9, 2026 postal ballot: preferential issue of 1,000,000 warrants to promoter Shailesh Siroya revised to ₹84/warrant, updated payment terms; proceeds for Greenfield API facility at Yadgiri.
